Continual reassessment method for partial ordering
From MaRDI portal
Publication:2893418
Recommendations
- Designs for Single- or Multiple-Agent Phase I Trials
- Continual reassessment and related dose-finding designs
- A Curve‐Free Method for Phase I Clinical Trials
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- On the consistency of the continual reassessment method with multiple toxicity constraints
Cites work
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Coherence principles in dose-finding studies
- Confidence interval estimation subject to order restrictions
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Designs for Single- or Multiple-Agent Phase I Trials
- Dose-finding with two agents in phase I oncology trials
- Non-parametric optimal design in dose finding studies
- Two‐Dimensional Dose Finding in Discrete Dose Space
Cited in
(25)- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials
- Improving safety of the continual reassessment method via a modified allocation rule
- Consistency of the when the curve is not monotone and its application to the POCRM
- Early completion of phase I cancer clinical trials with Bayesian optimal interval design
- Continual reassessment method for ordered groups
- A Curve‐Free Method for Phase I Clinical Trials
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
- A simulation-free approach to assessing the performance of the continual reassessment method
- Adaptive clinical trial designs for phase I cancer studies
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- Designs for Single- or Multiple-Agent Phase I Trials
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
- A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering
- Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
- A phase I dose-finding study based on polychotomous toxicity responses
- Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
- On the consistency of the continual reassessment method with multiple toxicity constraints
- Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial
- Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
This page was built for publication: Continual reassessment method for partial ordering
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2893418)
